Disease activity free status in MS

Multiple Sclerosis and Related Disorders

Volumn 1, Issue 1, 2012, Pages 6-7

  Lublin, Fred D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054701138     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2011.08.001     Document Type: Editorial

References (10)

1. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801.
2. Fabian MT, Lublin F, Wolinsky J. Evaluation of progressive relapsing MS patients in the PROMISE trial. Neurology 2011;76(9):A613.
3. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg SP, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362(5):416-26.
4. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011;10(4):329-37.
5. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing- Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8(3): 254-60.
6. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66(4):460-71.
7. Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, et al. Assessing changes in relapse rates in multiple sclerosis. Multiple Sclerosis 2010;16(12):1414-21.
8. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
9. Kappos L, Radue EW, O'Connor P, Amato M, Zhang-Auberson LX, Tang DJ, et al. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis: results from a Phase 3, Placebo- Controlled Study (FREEDOMS). Neurology 2011;76(9):A563.
10. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910.